This is not unexpected, given our recent finding that the survival of topotecan-treated animals carrying ABCG2-deficient Brca1−/−;p53−/− mammary tumors is markedly increased over that of animals with ABCG2-proficient tumors. The gene discussed is ABCG2; the disease is breast cancer.